• 1. Preparation of gas phase naked silver cluster cations outside a mass spectrometer from ligand protected clusters in solution
  Madhuri Jash,Arthur C. Reber,Atanu Ghosh,Depanjan Sarkar,Mohammad Bodiuzzaman,Pallab Basuri,Ananya Baksi,Shiv N. Khanna,Thalappil Pradeep Nanoscale 2018 10 15714
• 2. Au10Ag17(TPP)10(SR)6Cl5 nanocluster: structure, transformation and the origin of its photoluminescence
  Along Ma,Jiawei Wang,Jie Kong,Yonggang Ren,Yuxuan Wang,Xiaoshuang Ma,Meng Zhou,Shuxin Wang Phys. Chem. Chem. Phys. 2023 25 9772
• 3. Au10Ag17(TPP)10(SR)6Cl5 nanocluster: structure, transformation and the origin of its photoluminescence
  Along Ma,Jiawei Wang,Jie Kong,Yonggang Ren,Yuxuan Wang,Xiaoshuang Ma,Meng Zhou,Shuxin Wang Phys. Chem. Chem. Phys. 2023 25 9772
• 4. Distinct photophysical properties in atom-precise silver and copper nanocluster analogues
  Yan-Ling Li,Zhao-Yang Wang,Xiao-Hong Ma,Peng Luo,Chen-Xia Du,Shuang-Quan Zang Nanoscale 2019 11 5151
• 5. In situ synchrotron X-ray diffraction study of coherently embedded silver nanostructure growth in silicon
  Puspendu Guha,Raghavendra Rao Juluri,Anjan Bhukta,Arnab Ghosh,Santanu Maiti,Arpan Bhattacharyya,Velaga Srihari,Parlapalli V. Satyam CrystEngComm 2017 19 6811

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylpropanes
• Other Chemical additives Functional Additives
• Pharmaceutical and Biochemical Products Medical Target Class

Tyrphostin A9 (CAS No. 10537-47-0): A Comprehensive Overview of Its Biochemical Significance and Recent Research Applications

Tyrphostin A9, identified by its Chemical Abstracts Service (CAS) number 10537-47-0, is a well-documented compound that has garnered significant attention in the field of biochemical research. This molecule, belonging to the Tyrphostin family, is renowned for its potent inhibitory effects on various tyrosine kinases, making it a valuable tool in both academic and industrial research settings. The increasing interest in Tyrphostin A9 stems from its multifaceted applications, particularly in the study of signal transduction pathways and its potential role in therapeutic interventions.

The molecular structure of Tyrphostin A9 (CAS No. 10537-47-0) is characterized by its unique pharmacophoric features, which contribute to its high specificity and efficacy in targeting tyrosine kinase receptors. These structural attributes have been extensively studied to understand how they interact with biological targets, leading to a deeper comprehension of their mechanism of action. The compound’s ability to modulate signaling pathways has opened new avenues in the investigation of various diseases, including cancer and inflammatory disorders.

In recent years, Tyrphostin A9 has been extensively researched for its potential applications in oncology. Studies have demonstrated that it can inhibit the activity of key tyrosine kinases involved in tumor growth and progression. For instance, research published in the journal *Molecular Cancer Research* highlighted the inhibitory effect of Tyrphostin A9 on the epidermal growth factor receptor (EGFR), a critical player in many cancer types. This finding underscores the compound’s significance as a lead molecule for developing novel anticancer therapies.

Beyond oncology, Tyrphostin A9 (CAS No. 10537-47-0) has been explored for its role in regulating inflammatory responses. Chronic inflammation is a hallmark of numerous diseases, and modulating inflammatory pathways has become a key strategy in therapeutic development. Preliminary studies indicate that Tyrphostin A9 can attenuate inflammatory signaling by inhibiting specific tyrosine kinases involved in the release of pro-inflammatory cytokines. This property makes it a promising candidate for treating inflammatory conditions such as rheumatoid arthritis and atherosclerosis.

The synthesis and characterization of Tyrphostin A9 have also been subjects of considerable interest. Advanced synthetic methodologies have enabled researchers to produce high-purity batches of this compound, facilitating more accurate and reliable experimental outcomes. Techniques such as high-performance liquid chromatography (HPLC) and nuclear magnetic resonance (NMR) spectroscopy have been employed to confirm the structural integrity of synthesized derivatives, ensuring that researchers are working with consistent and well-defined molecules.

Moreover, the pharmacokinetic properties of Tyrphostin A9 have been scrutinized to optimize its delivery and efficacy. Studies have focused on improving its bioavailability and reducing potential side effects by modifying its chemical structure. For example, prodrugs derived from Tyrphostin A9 have been developed to enhance absorption and distribution within the body, thereby increasing therapeutic efficacy.

The role of computational modeling in understanding the interactions between Tyrphostin A9 (CAS No. 10537-47-0) and biological targets cannot be overstated. Molecular docking simulations have provided valuable insights into how this compound binds to tyrosine kinase receptors at the atomic level. These simulations help predict binding affinities and identify potential modifications that could enhance its potency or selectivity. Such computational approaches are increasingly integrated into drug discovery pipelines, streamlining the process of identifying promising candidates for further development.

In conclusion, Tyrphostin A9 represents a significant advancement in biochemical research due to its potent inhibitory effects on tyrosine kinases and its broad range of potential applications. The ongoing studies into its mechanisms of action, synthetic modifications, and pharmacokinetic properties continue to expand our understanding of this compound’s therapeutic potential. As research progresses, it is anticipated that derivatives and analogs of Tyrphostin A9 will emerge as powerful tools for addressing various medical challenges.

• 25751-79-5(Ethenetricarbonitrile, [3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-)
• 626202-63-9(Propanedinitrile, [bis(4-hydroxyphenyl)methylene]-)
• 66422-14-8(Benzeneacetonitrile, a-[bis(4-hydroxyphenyl)methylene]-)
• 65678-07-1(AG1024)
• 71308-35-5(Propanedinitrile,2-[(4-hydroxy-3,5-dimethylphenyl)methylene]-)
• 76457-46-0(2-Butenedinitrile, 2,3-bis(4-hydroxyphenyl)-, (Z)-)
• 76457-45-9(2-Butenedinitrile, 2,3-bis(4-hydroxyphenyl)-, (E)-)
• 19460-09-4(Benzeneacetonitrile, a-[(4-hydroxyphenyl)phenylmethylene]-, (Z)-)
• 6968-92-9(2-[(2-hydroxyphenyl)methylidene]propanedinitrile)
• 148741-33-7(Propanedinitrile,2-[[3-(1,1-dimethylethyl)-4,5-dihydroxyphenyl]methylene]-)